The reform of EU pharmaceutical legislation has moved from negotiation to implementation planning. Published analyses report that the Council adopted the texts in autumn 2026, with final steps and publication in the Official Journal awaited. Companies should plan against the transition calendar now.
What the reform replaces
The package consists of a new Directive on the Union code for human medicines and a new Regulation on Union procedures for authorisation and supervision. Among other acts, the Regulation repeals Regulation (EC) No 726/2004, the orphan Regulation (EC) No 141/2000 and the Paediatric Regulation (EC) No 1901/2006.
Indicative timetable
Law firm analyses published in October 2026 describe the following structure, relative to entry into force, which takes place 20 days after Official Journal publication:
- On entry into force: provisions such as the transferable exclusivity voucher for priority antimicrobials, regulatory sandboxes and critical medicine supply measures.
- After about six months: shortage monitoring and management obligations.
- After about one year: Member State requests that a holder place a product on its market.
- After about 24 months: most provisions of the Regulation and the main data and market protection changes.
Ongoing procedures
Applications, orphan designations and paediatric investigation plans submitted before the relevant application dates are expected to be completed under current rules. New rules will therefore bite on submissions from around late 2028, although some obligations arrive earlier.
Caution on dates
All dates depend on actual publication, and national transposition of the Directive may vary. Treat the calendar as a planning tool, and verify against the Official Journal.
How PQRA helps
PQRA helps companies map the reform onto their portfolios: which products fall under which rules, what operating model changes are needed and how to sequence submissions and lifecycle decisions across the transition.


No responses yet